News headlines about OvaScience (NASDAQ:OVAS) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.3454455664725 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Financial Survey: OvaScience (OVAS) vs. Chromadex (CDXC) (americanbankingnews.com)
- OvaScience (OVAS) and The Competition Financial Comparison (americanbankingnews.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline – January 22, 2018 (finance.yahoo.com)
- OvaScience (OVAS) Upgraded to “Buy” by Zacks Investment Research (americanbankingnews.com)
Several equities analysts have recently commented on OVAS shares. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of OvaScience in a research note on Monday, November 6th.
OvaScience (NASDAQ:OVAS) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.15. OvaScience had a negative return on equity of 68.71% and a negative net margin of 20,090.13%. equities analysts forecast that OvaScience will post -1.48 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/ovascience-ovas-getting-somewhat-positive-press-coverage-report-shows/1820905.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.